Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

Analysis of Short-term (Operating) Activity Ratios 
Quarterly Data

Microsoft Excel

Short-term Activity Ratios (Summary)

Bristol-Myers Squibb Co., short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Turnover Ratios
Inventory turnover 3.72 3.70 4.02 4.33 4.39 3.93 4.33 4.77 4.59 4.55 4.74 4.85 5.01 5.61 5.68 5.83 4.46 3.50 1.88
Payables turnover 3.05 3.12 3.28 3.75 3.38 3.20 3.33 3.82 3.41 3.25 3.37 3.89 2.97 3.69 4.34 4.65 3.73 3.23 3.30
Working capital turnover 12.50 15.56 4.60 10.47 5.53 5.55 8.30 5.75 4.92 6.24 3.95 4.43 4.24 4.25 3.72 2.77 3.09 2.38 2.28
Average No. Days
Average inventory processing period 98 99 91 84 83 93 84 76 79 80 77 75 73 65 64 63 82 104 194
Less: Average payables payment period 120 117 111 97 108 114 109 96 107 112 108 94 123 99 84 78 98 113 110

Based on: 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Short-term activity ratio Description The company
Inventory turnover An activity ratio calculated as cost of goods sold divided by inventory. Bristol-Myers Squibb Co. inventory turnover ratio deteriorated from Q4 2023 to Q1 2024 but then slightly improved from Q1 2024 to Q2 2024.
Payables turnover An activity ratio calculated as cost of goods sold divided by payables. Bristol-Myers Squibb Co. payables turnover ratio decreased from Q4 2023 to Q1 2024 and from Q1 2024 to Q2 2024.
Working capital turnover An activity ratio calculated as revenue divided by working capital. Bristol-Myers Squibb Co. working capital turnover ratio improved from Q4 2023 to Q1 2024 but then slightly deteriorated from Q1 2024 to Q2 2024.

Short-term activity ratio Description The company
Average inventory processing period An activity ratio equal to the number of days in the period divided by inventory turnover over the period. Bristol-Myers Squibb Co. number of days of inventory outstanding deteriorated from Q4 2023 to Q1 2024 but then slightly improved from Q1 2024 to Q2 2024.
Average payables payment period An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. Bristol-Myers Squibb Co. number of days of payables outstanding increased from Q4 2023 to Q1 2024 and from Q1 2024 to Q2 2024.

Inventory Turnover

Bristol-Myers Squibb Co., inventory turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Cost of products sold, excludes amortization of acquired intangible assets 3,267 2,932 2,745 2,506 2,876 2,566 2,593 2,353 2,720 2,471 2,356 2,291 2,452 2,841 2,910 2,502 2,699 3,662 2,492 1,790 1,972 1,824
Inventories 3,077 2,985 2,662 2,436 2,364 2,605 2,339 2,074 2,142 2,104 2,095 2,163 2,137 1,953 2,074 1,949 2,384 2,836 4,293 1,192 1,308 1,283
Short-term Activity Ratio
Inventory turnover1 3.72 3.70 4.02 4.33 4.39 3.93 4.33 4.77 4.59 4.55 4.74 4.85 5.01 5.61 5.68 5.83 4.46 3.50 1.88
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. 4.86 4.83 4.98 4.74 4.30 4.53 4.87 5.54 4.99 4.96 5.58 5.76 5.45 5.40 4.65 3.66 2.36 4.17 4.10
Amgen Inc. 1.42 1.14 0.89 1.41 1.38 1.31 1.30 1.34 1.40 1.48 1.58 1.53 1.53 1.53 1.58 1.48 1.38 1.31 1.22
Danaher Corp. 3.59 3.73 3.80 3.70 3.58 3.50 4.03 3.80 3.71 3.87 4.16 4.06 4.28 4.34 4.28 3.79 3.26 3.09 4.87
Eli Lilly & Co. 1.16 1.17 1.23 1.40 1.37 1.36 1.54 1.86 1.79 1.93 1.88 1.79 1.80 1.68 1.38 1.42 1.48 1.55 1.48
Gilead Sciences Inc. 3.33 3.59 3.64 3.49 3.45 3.57 3.75 4.71 4.50 4.50 4.08 3.21 2.99 2.79 2.72 4.82 4.52 4.75 5.07
Johnson & Johnson 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77 2.87 2.86 2.91 2.86 3.04 2.89 2.93 3.16 3.05
Merck & Co. Inc. 2.39 2.42 2.54 2.63 2.66 2.72 2.95 3.10 3.06 2.74 2.29 2.73 2.79 2.40 2.45 2.22 2.33 2.46 2.36
Moderna Inc. 8.47 13.55 23.23 11.67 6.35 7.09 5.71 2.14 2.12 1.77 1.82 1.73 1.48 0.41 0.17
Pfizer Inc. 2.05 2.15 2.45 2.65 2.31 3.07 3.82 3.62 3.66 3.67 3.40 2.78 1.80 1.28 1.08 0.90 1.05 1.15 1.23
Regeneron Pharmaceuticals Inc. 0.65 0.66 0.70 0.72 0.69 0.67 0.65 0.83 0.96 1.27 1.25 0.88 0.82 0.56 0.58 0.55 0.57 0.55 0.55
Thermo Fisher Scientific Inc. 4.83 4.93 5.06 4.83 4.64 4.62 4.60 4.29 4.03 3.87 3.88 3.90 4.03 4.01 4.02 3.92 3.93 4.14 4.22

Based on: 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q2 2024 Calculation
Inventory turnover = (Cost of products sold, excludes amortization of acquired intangible assetsQ2 2024 + Cost of products sold, excludes amortization of acquired intangible assetsQ1 2024 + Cost of products sold, excludes amortization of acquired intangible assetsQ4 2023 + Cost of products sold, excludes amortization of acquired intangible assetsQ3 2023) ÷ Inventories
= (3,267 + 2,932 + 2,745 + 2,506) ÷ 3,077 = 3.72

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Inventory turnover An activity ratio calculated as cost of goods sold divided by inventory. Bristol-Myers Squibb Co. inventory turnover ratio deteriorated from Q4 2023 to Q1 2024 but then slightly improved from Q1 2024 to Q2 2024.

Payables Turnover

Bristol-Myers Squibb Co., payables turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Cost of products sold, excludes amortization of acquired intangible assets 3,267 2,932 2,745 2,506 2,876 2,566 2,593 2,353 2,720 2,471 2,356 2,291 2,452 2,841 2,910 2,502 2,699 3,662 2,492 1,790 1,972 1,824
Accounts payable 3,751 3,539 3,259 2,813 3,069 3,194 3,040 2,595 2,882 2,944 2,949 2,695 3,609 2,972 2,713 2,441 2,852 3,069 2,445 1,888 2,005 1,976
Short-term Activity Ratio
Payables turnover1 3.05 3.12 3.28 3.75 3.38 3.20 3.33 3.82 3.41 3.25 3.37 3.89 2.97 3.69 4.34 4.65 3.73 3.23 3.30
Benchmarks
Payables Turnover, Competitors2
Amgen Inc. 5.01 6.10 5.32 5.22 5.67 4.97 4.08 5.30 5.09 4.65 4.72 5.41 4.92 4.40 4.33 5.01 4.60 3.60 3.18
Danaher Corp. 5.84 5.88 5.58 5.90 5.82 5.68 5.45 5.61 5.00 5.04 4.48 5.20 5.54 5.29 4.79 5.46 5.28 4.55 5.23
Eli Lilly & Co. 2.56 2.88 2.73 2.81 2.65 3.07 3.43 4.24 4.21 5.24 4.38 4.46 4.30 3.75 3.41 3.53 3.92 3.97 3.36
Gilead Sciences Inc. 12.57 10.69 11.81 9.90 9.06 8.99 6.25 11.22 11.89 11.43 9.36 9.18 8.70 8.71 5.42 9.22 8.93 7.94 6.56
Johnson & Johnson 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26 2.70 3.32 3.38 3.34 2.99 3.94 4.09 3.78 3.23
Merck & Co. Inc. 4.39 4.48 4.11 4.59 4.58 4.34 4.08 5.16 4.86 4.25 2.96 4.54 3.93 3.81 3.37 3.64 4.10 4.02 3.78
Moderna Inc. 12.12 21.84 9.03 11.50 14.65 13.34 11.12 13.48 22.50 17.29 8.67 19.23 12.35 25.12 0.43 0.00 0.00 0.00 0.00
Pfizer Inc. 4.60 4.19 3.72 5.07 3.92 4.78 5.04 5.49 6.17 6.66 5.53 5.11 3.72 2.68 2.02 2.02 2.32 2.45 2.42
Regeneron Pharmaceuticals Inc. 3.32 2.67 2.99 3.43 3.14 2.69 2.65 3.74 4.00 5.39 4.32 4.23 3.42 2.23 2.36 2.24 2.48 2.36 1.87
Thermo Fisher Scientific Inc. 9.85 9.91 8.97 10.41 10.82 9.35 7.67 9.93 8.84 7.96 6.83 8.31 8.88 8.12 7.45 8.82 10.35 8.93 7.40

Based on: 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q2 2024 Calculation
Payables turnover = (Cost of products sold, excludes amortization of acquired intangible assetsQ2 2024 + Cost of products sold, excludes amortization of acquired intangible assetsQ1 2024 + Cost of products sold, excludes amortization of acquired intangible assetsQ4 2023 + Cost of products sold, excludes amortization of acquired intangible assetsQ3 2023) ÷ Accounts payable
= (3,267 + 2,932 + 2,745 + 2,506) ÷ 3,751 = 3.05

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Payables turnover An activity ratio calculated as cost of goods sold divided by payables. Bristol-Myers Squibb Co. payables turnover ratio decreased from Q4 2023 to Q1 2024 and from Q1 2024 to Q2 2024.

Working Capital Turnover

Bristol-Myers Squibb Co., working capital turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Current assets 26,890 28,669 31,770 27,632 28,074 27,086 27,273 26,796 30,186 30,121 33,262 31,443 29,161 27,111 30,192 34,277 34,343 31,853 29,354 40,191 37,716 17,093
Less: Current liabilities 23,265 25,822 22,262 23,462 20,150 19,085 21,890 18,930 20,915 22,821 21,868 21,460 18,991 17,330 19,080 20,464 23,421 19,232 18,304 10,489 9,711 8,841
Working capital 3,625 2,847 9,508 4,170 7,924 8,001 5,383 7,866 9,271 7,300 11,394 9,983 10,170 9,781 11,112 13,813 10,922 12,621 11,050 29,702 28,005 8,252
 
Net product sales 11,925 11,559 11,168 10,645 10,917 11,048 11,065 10,813 11,485 11,308 11,609 11,243 11,405 10,798 10,766 10,197 9,817 10,541 7,662 5,768 6,031 5,713
Short-term Activity Ratio
Working capital turnover1 12.50 15.56 4.60 10.47 5.53 5.55 8.30 5.75 4.92 6.24 3.95 4.43 4.24 4.25 3.72 2.77 3.09 2.38 2.28
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc. 130.12 0.97 0.98
Amgen Inc. 5.19 3.39 2.25 0.81 0.84 0.82 3.82 2.52 3.67 4.34 3.37 2.55 5.35 2.84 2.55 1.87 1.87 3.27 3.96
Danaher Corp. 8.10 3.60 4.22 2.29 3.08 3.81 4.20 5.00 5.43 5.91 8.40 7.98 3.12 3.45 3.48 3.14 2.80 6.74 0.87
Eli Lilly & Co. 12.62 5.45 31.79 12.21 5.77 31.84 14.71 19.45 8.19 8.33 6.73 12.14 5.21 4.93 5.45 8.85 16.68 11.54
Gilead Sciences Inc. 17.98 26.58 5.61 6.74 84.15 9.14 8.42 8.56 6.87 6.68 8.54 7.25 7.09 7.06 5.30 1.07 1.55 1.24 1.08
Johnson & Johnson 22.29 10.35 11.81 9.37 14.06 23.02 4.88 5.02 5.57 5.95 5.97 5.93 7.26 9.44 4.32 8.83 7.85 8.81
Merck & Co. Inc. 5.14 9.68 9.29 6.69 8.86 5.63 5.16 5.58 6.39 6.09 7.62 6.51 6.97 84.97 109.83 7.67 6.59 17.87 8.90
Moderna Inc. 0.67 0.69 0.91 1.36 1.35 1.66 2.17 2.74 3.29 3.07 2.55 3.15 2.88 0.59 0.10 0.00 0.00 0.00 0.00
Pfizer Inc. 28.72 1.60 2.01 6.88 11.00 3.83 5.05 6.10 4.78 4.29 4.21 3.60 4.58 3.16 3.31 57.45
Regeneron Pharmaceuticals Inc. 0.87 0.86 0.82 0.87 0.92 0.90 0.96 1.09 1.14 1.46 1.59 1.35 1.29 1.35 1.20 1.22 1.92 1.21 1.41
Thermo Fisher Scientific Inc. 3.96 4.38 4.05 4.86 7.40 10.13 5.46 5.40 6.03 6.13 5.87 2.30 3.10 3.36 2.76 2.37 2.69 3.54 4.48

Based on: 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q2 2024 Calculation
Working capital turnover = (Net product salesQ2 2024 + Net product salesQ1 2024 + Net product salesQ4 2023 + Net product salesQ3 2023) ÷ Working capital
= (11,925 + 11,559 + 11,168 + 10,645) ÷ 3,625 = 12.50

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Working capital turnover An activity ratio calculated as revenue divided by working capital. Bristol-Myers Squibb Co. working capital turnover ratio improved from Q4 2023 to Q1 2024 but then slightly deteriorated from Q1 2024 to Q2 2024.

Average Inventory Processing Period

Bristol-Myers Squibb Co., average inventory processing period calculation (quarterly data)

Microsoft Excel
Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data
Inventory turnover 3.72 3.70 4.02 4.33 4.39 3.93 4.33 4.77 4.59 4.55 4.74 4.85 5.01 5.61 5.68 5.83 4.46 3.50 1.88
Short-term Activity Ratio (no. days)
Average inventory processing period1 98 99 91 84 83 93 84 76 79 80 77 75 73 65 64 63 82 104 194
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. 75 75 73 77 85 81 75 66 73 74 65 63 67 68 79 100 155 88 89
Amgen Inc. 257 321 411 259 265 279 281 272 260 247 231 239 239 239 231 247 265 279 300
Danaher Corp. 102 98 96 99 102 104 91 96 98 94 88 90 85 84 85 96 112 118 75
Eli Lilly & Co. 316 312 298 261 267 268 237 196 204 189 194 204 203 217 265 257 247 236 247
Gilead Sciences Inc. 110 102 100 105 106 102 97 78 81 81 89 114 122 131 134 76 81 77 72
Johnson & Johnson 166 158 154 149 164 155 147 136 136 132 127 128 125 128 120 126 124 116 119
Merck & Co. Inc. 153 151 144 139 137 134 124 118 119 133 159 134 131 152 149 164 156 148 155
Moderna Inc. 43 27 16 31 57 51 64 170 172 206 201 211 247 897 2,141
Pfizer Inc. 178 170 149 138 158 119 95 101 100 99 107 131 203 284 338 405 348 316 296
Regeneron Pharmaceuticals Inc. 562 553 519 508 532 549 562 440 379 287 292 415 445 653 625 664 635 659 661
Thermo Fisher Scientific Inc. 76 74 72 76 79 79 79 85 91 94 94 94 91 91 91 93 93 88 87

Based on: 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q2 2024 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 3.72 = 98

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average inventory processing period An activity ratio equal to the number of days in the period divided by inventory turnover over the period. Bristol-Myers Squibb Co. number of days of inventory outstanding deteriorated from Q4 2023 to Q1 2024 but then slightly improved from Q1 2024 to Q2 2024.

Average Payables Payment Period

Bristol-Myers Squibb Co., average payables payment period calculation (quarterly data)

Microsoft Excel
Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data
Payables turnover 3.05 3.12 3.28 3.75 3.38 3.20 3.33 3.82 3.41 3.25 3.37 3.89 2.97 3.69 4.34 4.65 3.73 3.23 3.30
Short-term Activity Ratio (no. days)
Average payables payment period1 120 117 111 97 108 114 109 96 107 112 108 94 123 99 84 78 98 113 110
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc. 73 60 69 70 64 73 90 69 72 78 77 67 74 83 84 73 79 101 115
Danaher Corp. 63 62 65 62 63 64 67 65 73 72 82 70 66 69 76 67 69 80 70
Eli Lilly & Co. 142 127 134 130 138 119 106 86 87 70 83 82 85 97 107 103 93 92 109
Gilead Sciences Inc. 29 34 31 37 40 41 58 33 31 32 39 40 42 42 67 40 41 46 56
Johnson & Johnson 121 113 132 111 133 120 137 118 116 112 135 110 108 109 122 93 89 97 113
Merck & Co. Inc. 83 81 89 80 80 84 89 71 75 86 123 80 93 96 108 100 89 91 97
Moderna Inc. 30 17 40 32 25 27 33 27 16 21 42 19 30 15 845
Pfizer Inc. 79 87 98 72 93 76 72 66 59 55 66 71 98 136 181 180 157 149 151
Regeneron Pharmaceuticals Inc. 110 137 122 106 116 136 138 98 91 68 84 86 107 164 155 163 147 155 195
Thermo Fisher Scientific Inc. 37 37 41 35 34 39 48 37 41 46 53 44 41 45 49 41 35 41 49

Based on: 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q2 2024 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 3.05 = 120

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average payables payment period An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. Bristol-Myers Squibb Co. number of days of payables outstanding increased from Q4 2023 to Q1 2024 and from Q1 2024 to Q2 2024.